PL350228A1 - Dimeric compounds and as inhibitors of neuraminidase - Google Patents

Dimeric compounds and as inhibitors of neuraminidase

Info

Publication number
PL350228A1
PL350228A1 PL00350228A PL35022800A PL350228A1 PL 350228 A1 PL350228 A1 PL 350228A1 PL 00350228 A PL00350228 A PL 00350228A PL 35022800 A PL35022800 A PL 35022800A PL 350228 A1 PL350228 A1 PL 350228A1
Authority
PL
Poland
Prior art keywords
neuraminidase
inhibitors
dimeric compounds
dimeric
compounds
Prior art date
Application number
PL00350228A
Other languages
English (en)
Inventor
Wen-Yang Wu
Betty Jin
Original Assignee
Biota Scient Management
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scient Management filed Critical Biota Scient Management
Publication of PL350228A1 publication Critical patent/PL350228A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL00350228A 1999-03-12 2000-03-09 Dimeric compounds and as inhibitors of neuraminidase PL350228A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP9139A AUPP913999A0 (en) 1999-03-12 1999-03-12 Novel chemical compounds and their use

Publications (1)

Publication Number Publication Date
PL350228A1 true PL350228A1 (en) 2002-11-18

Family

ID=3813338

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00350228A PL350228A1 (en) 1999-03-12 2000-03-09 Dimeric compounds and as inhibitors of neuraminidase

Country Status (26)

Country Link
US (1) US6548476B1 (enExample)
EP (1) EP1165541B1 (enExample)
JP (1) JP5160000B2 (enExample)
KR (1) KR100805906B1 (enExample)
CN (1) CN1343205A (enExample)
AP (1) AP2001002277A0 (enExample)
AT (1) ATE295361T1 (enExample)
AU (2) AUPP913999A0 (enExample)
BR (1) BR0008939A (enExample)
CA (1) CA2367755C (enExample)
CZ (1) CZ20013274A3 (enExample)
DE (1) DE60020100T2 (enExample)
EA (1) EA200100968A1 (enExample)
ES (1) ES2241581T3 (enExample)
HK (1) HK1041693B (enExample)
HU (1) HUP0200190A3 (enExample)
ID (1) ID29868A (enExample)
IL (1) IL145346A (enExample)
MX (1) MXPA01009203A (enExample)
NO (1) NO327812B1 (enExample)
NZ (1) NZ514041A (enExample)
PL (1) PL350228A1 (enExample)
TR (1) TR200102794T2 (enExample)
TW (1) TWI268279B (enExample)
WO (1) WO2000055149A1 (enExample)
ZA (1) ZA200107450B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901081T2 (xx) * 1996-11-14 1999-08-23 Biota Scientific Management Pty.Ltd. Y�ntem ve bu y�ntemde kullan�lan yeni bile�imler.
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
AUPR001000A0 (en) * 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
JP5183853B2 (ja) * 2001-11-09 2013-04-17 バイオタ、サイアンティフィック、マネージメント、プロプライエタリ、リミテッド 二量体化合物および抗ウイルス薬としてのそれらの使用
AU2002336823B2 (en) * 2001-11-09 2008-03-20 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
AUPR879601A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879701A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AU2002340635B2 (en) * 2001-11-09 2008-03-13 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
AU2002340632B2 (en) * 2001-11-09 2008-03-20 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
AUPR879401A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879501A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
KR20120104412A (ko) 2002-09-06 2012-09-20 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US7314949B2 (en) 2004-12-04 2008-01-01 Xerox Corporation Trans-1,2-cyclohexane bis(urea-urethane) compounds
US7144450B2 (en) * 2004-12-04 2006-12-05 Xerox Corporation Phase change inks containing trans-1,2-cyclohexane bis(urea-urethane) compounds
US7220300B2 (en) 2004-12-04 2007-05-22 Xerox Corporation Phase change inks containing bis(urea-urethane) compounds
US7153349B2 (en) 2004-12-04 2006-12-26 Xerox Corporation Phase change inks containing curable trans-1,2-cyclohexane bis(urea-urethane) compounds
US7560587B2 (en) * 2004-12-04 2009-07-14 Xerox Corporation Bis[urea-urethane] compounds
US7317122B2 (en) 2004-12-04 2008-01-08 Xerox Corporation Curable trans-1,2-cyclohexane bis(urea-urethane) compounds
US7576235B2 (en) 2004-12-04 2009-08-18 Xerox Corporation Processes for preparing bis(urea-urethane) compounds
US8227425B2 (en) * 2007-01-23 2012-07-24 Therapicon Srl Antiviral compounds
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP2173759A4 (en) * 2007-07-03 2014-01-29 Childrens Hosp & Res Ct Oak OLIGOSIAL INSERTS, PROCESS FOR THEIR PREPARATION AND ITS IMMUNOLOGICAL USE
US8097591B2 (en) * 2007-07-03 2012-01-17 Children's Hospital & Research Center Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
WO2009006591A1 (en) 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Inhibitors of polysialic acid de-n-acetylase and methods for using the same
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
JP5855568B2 (ja) * 2009-09-15 2016-02-09 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
NL2005389A (en) 2009-10-21 2011-04-26 Asml Netherlands Bv Lithographic apparatus, device manufacturing method, and method of applying a pattern to a substrate.
IT1396620B1 (it) * 2009-11-25 2012-12-14 Therapicon Srl Analoghi chimerici
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
EP2609105B1 (en) * 2010-08-24 2016-03-09 Imperial Innovations Limited Glycodendrimers of polypropyletherimine
HK1200106A1 (en) * 2012-01-05 2015-07-31 阿拉维制药公司 Formulations for enhanced bioavailability of zanamivir
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
KR102298172B1 (ko) 2013-09-06 2021-09-06 아카데미아 시니카 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
CA2950440A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
CN107074945B (zh) 2014-05-27 2021-08-24 中央研究院 增进抗体功效的通用糖型的组合物及方法
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
KR102422375B1 (ko) 2014-09-08 2022-07-18 아카데미아 시니카 당지질을 사용한 인간 iNKT 세포 활성화
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3248005B1 (en) 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
ES2911027T3 (es) * 2015-11-20 2022-05-17 AusVir Therapeutics Pty Ltd Compuestos para aplicaciones medicinales
RU2612221C1 (ru) * 2015-12-16 2017-03-03 Общество с ограниченной ответственностью "Синтавр" Блокаторы вируса гриппа
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CN108003065B (zh) * 2016-10-27 2021-01-08 中国石油化工股份有限公司 一种具有增稠作用的化合物和润滑脂以及它们的制备方法
WO2018199798A1 (ru) * 2017-04-28 2018-11-01 Общество с ограниченной ответственностью "Синтавр" Пептидные производные противовирусного препарата занамивира
AU2018273411B2 (en) * 2017-05-25 2022-12-01 The Governors Of The University Of Alberta Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
CN111698999A (zh) * 2017-12-06 2020-09-22 阿道恰公司 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph为7的可注射溶液
SG11202103313RA (en) * 2018-09-06 2021-04-29 Cidara Therapeutics Inc Compositions and methods for the treatment of viral infections
EP3860991A4 (en) * 2018-10-05 2022-11-16 Emory University MONOMERIC AND MULTIMERIC ANTI-HBV AGENTS
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2050484A1 (en) * 1990-02-27 1991-08-28 Satoru Nakabayashi Sialic acid-containing glycolipid derivatives
WO1992016640A1 (en) * 1991-03-18 1992-10-01 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
JPH07504222A (ja) * 1992-02-19 1995-05-11 ザ・バイオメンブレイン・インスティテュート 化学的に規定されるオリゴ糖，該オリゴ糖の誘導体，擬態物及び該オリゴ糖に対する抗体による細胞接着の抑制
JPH0638784A (ja) * 1992-03-30 1994-02-15 Meiji Milk Prod Co Ltd シアル酸を構成要素とする糖鎖の製造方法
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
SI9620042A (sl) * 1995-02-27 1998-12-31 Gilead Sciences, Inc. Novi selektivni inhibitorji virusnih ali bakterijskih neuraminidaz
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
WO1997032214A1 (en) 1996-03-01 1997-09-04 Biota Scientific Management Pty. Ltd. Method of detection of influenza virus and compounds for use therein
US5891862A (en) * 1996-03-15 1999-04-06 Geltex Pharmaceuticals, Inc. Polyvalent polymers for the treatment of rotavirus infection
AUPO104396A0 (en) 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Antiviral linear polymers
CA2261877C (en) * 1996-07-23 2009-04-07 Seikagaku Corporation Novel lactosamine oligosaccharide and method for producing the same
TR199901081T2 (xx) 1996-11-14 1999-08-23 Biota Scientific Management Pty.Ltd. Y�ntem ve bu y�ntemde kullan�lan yeni bile�imler.
JPH10182686A (ja) * 1996-12-26 1998-07-07 Ngk Insulators Ltd ガングリオシドＧＱ１ｂ類縁物質
US6267242B1 (en) 1997-04-17 2001-07-31 Johnson & Johnson Medical Kabushiki Kaisha Chemical indicator sheets and packaging bags for sterilization made with the use of the same
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein

Also Published As

Publication number Publication date
KR20020005617A (ko) 2002-01-17
EP1165541B1 (en) 2005-05-11
AU774222B2 (en) 2004-06-17
NO20014409D0 (no) 2001-09-11
HUP0200190A3 (en) 2004-01-28
ZA200107450B (en) 2002-09-10
HK1041693A1 (en) 2002-07-19
HK1041693B (en) 2005-10-14
NO20014409L (no) 2001-11-01
BR0008939A (pt) 2001-12-18
EP1165541A4 (en) 2002-06-05
AUPP913999A0 (en) 1999-04-01
US6548476B1 (en) 2003-04-15
ES2241581T3 (es) 2005-11-01
DE60020100D1 (de) 2005-06-16
MXPA01009203A (es) 2002-08-20
CA2367755C (en) 2007-08-28
JP2002539204A (ja) 2002-11-19
DE60020100T2 (de) 2006-01-19
IL145346A (en) 2005-11-20
ID29868A (id) 2001-10-18
CZ20013274A3 (cs) 2002-03-13
CA2367755A1 (en) 2000-09-21
AU2896600A (en) 2000-10-04
ATE295361T1 (de) 2005-05-15
TWI268279B (en) 2006-12-11
NZ514041A (en) 2001-09-28
TR200102794T2 (tr) 2002-09-23
AP2001002277A0 (en) 2001-09-30
NO327812B1 (no) 2009-09-28
CN1343205A (zh) 2002-04-03
KR100805906B1 (ko) 2008-02-21
JP5160000B2 (ja) 2013-03-13
HUP0200190A2 (en) 2002-06-29
EP1165541A1 (en) 2002-01-02
EA200100968A1 (ru) 2002-02-28
WO2000055149A1 (en) 2000-09-21
IL145346A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
NZ514041A (en) Dimeric compounds and as inhibitors of neuraminidase
IL149118A0 (en) Inhibitors of neuraminidases
AP2001002298A0 (en) Inhibitors of impdh enzyme
HUP0200391A2 (en) Use of pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth
HUP0202251A3 (en) Heterocyclic containing biphenyl ap2 inhibitors and application
HUP0100142A3 (en) Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
IL157659A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
AU4166400A (en) Alkenyl and alkynyl compounds as inhibitors of factor xa
HUP0105160A3 (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-betha-cyclodextrin or 2-hydroxypropyl-betha-cyclodextrin and method for its preparation and pharmaceutical compositions containing them
HUP0201334A3 (en) Hydrochloride of fused-heterocycle compound and pharmaceutical compositions containing the same
IL146000A0 (en) Ace-2 inhibiting compounds and methods of use thereof
ZA988469B (en) Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors
AU5619400A (en) Statine-derived tetrapeptide inhibitors of beta-secretase
HUP0202891A3 (en) Biphenyl derivatives used as nhe-3 inhibitors and pharmaceutical compositions containing them
PL335378A1 (en) Derivatives of inverse hydroxamates as metaloprotease inhibitors
HUP0201925A3 (en) Cyclic peptide derivatives as inhibitors of integrin alphavbeta6 and their use
IL131047A0 (en) Use of il-18 inhibitors
PL352200A1 (en) Inhibitors of viia agent
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
PL343678A1 (en) Pyrrolidines as inhibitors of neuraminidases
AU8005100A (en) Inhibitors of neuraminidases
AU7608100A (en) 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
PL352374A1 (en) Inhibitors of integrine o v beta 6
PL350963A1 (en) Use of arylalkanoylpyridazines